100% Phase 1/2 responders and BTD in hand; Embolden's single-arm topline determines whether NGN-401 becomes the first Rett gene therapy approved

Neurogene is a clinical-stage gene therapy company developing NGN-401 for Rett syndrome, a rare neurological disease; the treatment is not yet approved, though it has received Breakthrough Therapy designation based on early trial results.

Every one of ten Phase 1/2 participants improved on the CGI-I scale, gaining 4.7 developmental milestones on average with no plateau through 30 months, a signal strong enough to earn Breakthrough Therapy designation. The thesis resolves on whether Embolden's single-arm, open-label design clears the FDA's 33%-responder bar, since single-arm data without a concurrent control carries inherent approvability risk. Taysha and ProQR are pursuing Rett with gene therapy and RNA editing respectively, though neither has matched NGN-401's clinical dataset or regulatory standing to date.